MedTrace Logo

A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis

NCT03345589 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-05-03

No results posted yet for this study

Summary

This study evaluates the effect of 18-22mg/kg/d Ursodeoxycholic in refractory Primary Biliary Cholangitis

Conditions

Interventions

DRUG

18-22mg/kg/d Ursodeoxycholic

18-22mg/kg/d Ursodeoxycholic

DRUG

13-15mg/kg/d Ursodeoxycholic

13-15mg/kg/d Ursodeoxycholic

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Li Yang, MD · West China Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-30
Primary Completion
2018-12-01
Completion
2019-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03345589 on ClinicalTrials.gov